Volume 7.09 | Mar 11

Prostate Cell News 7.09 March 11, 2016
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PCN on Twitter
 
TOP STORY
Novel Molecular Processes Controlling Key Genes in Prostate Cancer Uncovered
Researchers have elucidated gene regulatory mechanisms that can explain how known genetic variants influence prostate cancer risk. The findings reveal widespread deregulation of androgen receptor function, a key player in prostate cancer. [Press release from Karolinska Institutet discussing online prepublication in Nature Genetics] Press Release | Abstract
Enter for a chance to win ISSCR 2016 Travel Support Award to San Francisco!
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer
Investigators assessed ErbB2 activity in abiraterone-resistant prostate cancer, and determined whether it may contribute to androgen receptor signaling in these tumors. [Clin Cancer Res] Abstract

Dietary Pterostilbene Is a Novel MTA1-Targeted Chemopreventive and Therapeutic Agent in Prostate Cancer
Researchers determined metastasis-associated protein 1 (MTA1)-targeted chemopreventive and therapeutic efficacy of pterostilbene, a natural potent analog of resveratrol, in pre-clinical models of prostate cancer. [Oncotarget] Full Article

Edelfosine Promotes Apoptosis in Androgen Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
Researchers investigated the effects of edelfosine combined with androgen deprivation in LNCaP and VCaP human prostate cancer cells. [Mol Cancer Ther] Abstract

Androgen Deprivation in LNCaP Prostate Tumor Xenografts Induces Vascular Changes and Hypoxic Stress, Resulting in Promotion of Epithelial-to-Mesenchymal Transition
Scientists hypothesised that an initial treatment response that increases tumor hypoxia drives selection of more malignant tumors. [Br J Cancer] Abstract

MiR-185 Attenuates Androgen Receptor Function in Prostate Cancer Indirectly by Targeting Bromodomain Containing 8 Isoform 2, an Androgen Receptor Co-Activator
Scientists studied interactions between miR-185 and the bromodomain containing 8 isoform 2 (BRD8 ISO2) to investigate indirect mechanisms of miR-185 with respect to androgen receptor function through BRD8 ISO2 in prostate cancer. [Mol Cell Endocrinol] Abstract

The Androgen Receptor Regulates PPARγ Expression and Activity in Human Prostate Cancer Cells
Investigators examined whether the androgen receptor (AR) regulates peroxisome proliferator activated receptor gamma (PPARγ) expression and function within human prostate cancer cells. qRT-PCR and Western blot analyses revealed nanomolar concentrations of the AR agonist dihydrotestosterone decrease PPARγ mRNA and protein within the castration-resistant, AR-positive C4-2 and VCaP human prostate cancer cell lines. [J Cell Physiol] Abstract

PCA3 Long Noncoding RNA Modulates the Expression of Key Cancer-Related Genes in LNCaP Prostate Cancer Cells
To further comprehend the mechanisms by which prostate cancer antigen 3 (PCA3) modulates LNCaP cell survival, researchers characterized the expression patterns of several cancer-related genes, including those involved in epithelial-mesenchymal transition and androgen receptor cofactors in response to PCA3 silencing. [Tumour Biol] Abstract

CLINICAL RESEARCH

TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-Resistant Prostate Cancer
The authors evaluated TMPRSS2-ERG expression using quantitative reverse transcription polymerase chain reaction in peripheral blood mononuclear cells and tumor tissue from metastatic resistant prostate cancer patients treated with taxanes. They examined peripheral blood mononuclear cells from 24 healthy controls, 50 patients treated with docetaxel, and 22 with cabazitaxel. [Eur Urol] Abstract

ProstaCult™: Serum-Free, BPE-Free Medium for Mouse Prostate Colony Assays FREE Sample Request
 
REVIEWS
Enhancing Active Surveillance of Prostate Cancer: The Potential of Exercise Medicine
Preliminary evidence suggests that lifestyle and/or exercise interventions might have therapeutic potential in this growing population of men with prostate cancer. However, several important issues remain unclear: the exact value of different types of lifestyle and exercise medicine interventions during active surveillance; the biological mechanisms of exercise in delaying disease progression; and the influence of the anxieties and distress created by having a diagnosis of cancer without then receiving active treatment. [Nat Rev Urol] Abstract

Active Surveillance for Prostate Cancer: Current Evidence and Contemporary State of Practice
Active surveillance (AS) has emerged as a primary management strategy in men with favourable-risk disease, and contemporary data suggest that use of AS has increased worldwide. Although published surveillance cohorts differ by protocol, reported rates of metastatic disease and prostate-cancer-specific mortality are exceedingly low in the intermediate term. [Nat Rev Urol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
 
INDUSTRY NEWS
NeoTract, Inc. Announces First Patients Enrolled in New Study to Expand UroLift® System Indication
NeoTract, Inc. announced that the first patients have been enrolled in the MedLift™ U.S. IDE trial. The study is designed to demonstrate safety and effectiveness of the UroLift® System for the treatment of patients with benign prostatic hyperplasia who have an obstructive median lobe, which is currently contraindicated in the United States. [NeoTract, Inc.] Press Release

Ipsen and PeptiMimesis Announce a Research Partnership in Oncology
Ipsen and PeptiMimesis announced the signature of a research partnership and a licensing option for the development and marketing of novel therapeutic peptides in oncology. The target receptor is involved in different phases of cancer development, including angiogenesis, immune tolerance and proliferation. [Ipsen] Press Release

From our sponsor: Learn about applications of ALDHbr cells in regenerative medicine. Watch the video.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW International Society for Stem Cell Research (ISSCR) 2016 Annual Meeting
June 22-25, 2016
San Francisco, United States

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Fellowship – Optical Imaging of Prostate Cancer (CEA Tech)

NEW PhD Studentship – Wnt Signaling in Stem Cells and Cancer (German Cancer Research Center)

Computational Biologist – Prostate Cancer (Australian Prostate Cancer Research Centre)

PhD Studentship – Genome Sequencing Technologies in Prostate Cancer (University of East Anglia)

PhD Studentship – Aggressive Prostate Cancer (University of East Anglia)

Postdoctoral Fellowship – Prostate and Breast Cancer Molecular Mechanisms (Feinberg School of Medicine)

Tenure Track Faculty Positions – Various Methods in Cancer Biology (Paul L. Foster School of Medicine)

Postdoctoral Fellowship – Epidemiology of Prostate Cancer (Fred Hutchinson Cancer Research Center)

Research Group Leader – Stress Regulated Processes During Oncogenesis (INSERM)

Postdoctoral Fellowship – Cancer Epigenomics (Princess Margaret Cancer Centre)

Postdoctoral Fellowship – Prostate Cancer Biology (Medical University of South Carolina )

Postdoctoral Fellowship – Prostate Cancer and Cancer Metabolism (Cleveland Clinic)

Post-Doc Fellowship – Metastasis of Cancer (University of Arizona Cancer Center)

Postdoctoral Research Fellow – Cell Cycle Control and Tumorigenesis (Fred Hutchinson Cancer Research Center)

Division Head – Medical Oncology (Fred Hutchinson Cancer Research Center)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us